EYLEA Injection Approved for Treatment of Macular Edema Following CRVO In Japan

Regeneron Pharmaceuticals (NASDAQ: REGN ) today announced that EYLEA® (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO) from the Japanese Ministry of Health, Labour and Welfare. "We are pleased with the approval of EYLEA in Japan in the macular edema